AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29889248 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 29133
Study 29889248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study 28248690 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage treatment (12 twice-weekly 45-min sessions focusing on trigger point release)
Number of subjects: 62
Study 28248690 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound sessions
Number of subjects: 62
Study 28248690 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 62
Study 26018634 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg)
Number of subjects: 287
Study 26018634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 24316711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Number of subjects: 42
Study 24316711 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 42
Study 24316711 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 42
Study 24316711 — intervention group
Group type: EXPERIMENTAL
Intervention: All NSAIDs (Diclofenac, Naproxen, Etodolac)
Number of subjects: 42
Study 21646442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 51
Study 21646442 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 51
Study 20809213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 28
Study 20809213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17908625 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief chemotherapy and involved-field radiation
Number of subjects: 0
Study 17908625 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief chemotherapy alone
Number of subjects: 0
Study 16296963 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol/chlorhexidine hand hygiene solution (ACHRS)
Number of subjects: 0
Study 16296963 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11937123 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (performed 25 minutes before and after embryo transfer)
Number of subjects: 160
Study 11937123 — intervention group
Group type: COMPARATOR
Intervention: Control group (embryo transfer without any supportive therapy)
Number of subjects: 160
Study 9742523 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 7 x 10(5) U, 5-fluorouracil (5-FU) 250 mg/day continuous infusion, mitomycin C (MMC) 4 mg once weekly for unresectable liver metastases
Number of subjects: 43
Study 9742523 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 1.4 to 2.1 x 10(6) U, 5-FU 250 mg, MMC 2 to 4 mg weekly for 6 months for resectable liver metastases
Number of subjects: 43
Study 10150444 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and in-depth education on HIV/AIDS
Number of subjects: 548
Study 10150444 — intervention group
Group type: COMPARATOR
Intervention: Ordinary traditional education
Number of subjects: 548
Study 2684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 2g IV once daily
Number of subjects: 51
Study 2684552 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime, 2g IV thrice daily
Number of subjects: 51
Study 866797 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of stilbestrol daily
Number of subjects: 2911
Study 866797 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2911
Study 31945399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter/Placebo
Number of subjects: 68
Study 31945399 — intervention group
Group type: COMPARATOR
Intervention: Bitter/No-Placebo
Number of subjects: 68
Study 31945399 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 68
Study 31343440 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 120 mg (subcutaneous injection, monthly for 52 weeks)
Number of subjects: 500
Study 31343440 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 120 mg
Number of subjects: 500
Study 28045670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mg I/mL
Number of subjects: 253
Study 28045670 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 370 mg I/mL
Number of subjects: 253
Study 25762499 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 30
Study 25762499 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACFP
Number of subjects: 30
Study 25762499 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF
Number of subjects: 30
Study 23349444 — intervention group
Group type: EXPERIMENTAL
Intervention: proADM
Number of subjects: 313
Study 23349444 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 313
Study 20937606 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant 300 mg
Number of subjects: 0
Study 20937606 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant 150 mg
Number of subjects: 0
Study 20937606 — intervention group
Group type: EXPERIMENTAL
Intervention: zolmitriptan 5 mg
Number of subjects: 0
Study 20937606 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 20937606 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant 300 mg vs zolmitriptan
Number of subjects: 0
Study 19536906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily (n=101)
Number of subjects: 150
Study 19536906 — intervention group
Group type: COMPARATOR
Intervention: High-dose imatinib 800 mg (n=49)
Number of subjects: 150
Study 17402663 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete-face format
Number of subjects: 0
Study 17402663 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-face format
Number of subjects: 0
Study 17402663 — intervention group
Group type: COMPARATOR
Intervention: Viewpoint transformation
Number of subjects: 0
Study 15385371 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine 12.5 mg/h (5 mL/h)
Number of subjects: 40
Study 15385371 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 5 mL/h via a catheter
Number of subjects: 40
Study 11414677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction (750 kcal/d; n = 16)
Number of subjects: 24
Study 11414677 — intervention group
Group type: COMPARATOR
Intervention: Energy balance (control; n = 8)
Number of subjects: 24
Study 10052544 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 203
Study 10052544 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (250 mg twice daily for 10 days)
Number of subjects: 203
Study 10052544 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 203
Study 10052544 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 203
Study 10052544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 203
Study 7998667 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day, administered twice daily)
Number of subjects: 56
Study 7998667 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) (31.2 mg/day, administered six times per day)
Number of subjects: 56
Study 3041940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy
Number of subjects: 224
Study 3041940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 31486166 — intervention group
Group type: COMPARATOR
Intervention: High coffee intake (>6 cups daily)
Number of subjects: 114220
Study 31486166 — intervention group
Group type: COMPARATOR
Intervention: Higher coffee intake (measured as a continuous variable)
Number of subjects: 114220
Study 31486166 — intervention group
Group type: COMPARATOR
Intervention: One cup per day higher coffee intake
Number of subjects: 114220
Study 31486166 — intervention group
Group type: COMPARATOR
Intervention: Genetic odds ratio for coffee intake
Number of subjects: 114220
Study 30767588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Kids programme
Number of subjects: 79
Study 28982836 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-force irrigated RF ablation
Number of subjects: 348
Study 28982836 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration cryoballoon ablation (2 min applications)
Number of subjects: 348
Study 28982836 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard duration cryoballoon ablation (4 min applications)
Number of subjects: 348
Study 25497115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (GRAS dose)
Number of subjects: 14
Study 25497115 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of sodium benzoate)
Number of subjects: 14
Study 24481930 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 75 μg with bupivacaine
Number of subjects: 60
Study 24481930 — intervention group
Group type: EXPERIMENTAL
Intervention: IT morphine 150 μg with bupivacaine
Number of subjects: 60
Study 21515841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 95
Study 21515841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 18608658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Attention to Response Task (SART)
Number of subjects: 0
Study 18608658 — intervention group
Group type: COMPARATOR
Intervention: Standard response format
Number of subjects: 0
Study 18608658 — intervention group
Group type: EXPERIMENTAL
Intervention: SART
Number of subjects: 0
Study 15907359 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB, 3M)
Number of subjects: 20
Study 15907359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentastic UNO (UNO, Pulpdent)
Number of subjects: 20
Study 12757449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg)
Number of subjects: 15
Study 12757449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12757449 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal supplements (23 commonly used)
Number of subjects: 15
Study 10669688 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 microg plus placebo (group 1)
Number of subjects: 213
Study 10669688 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg plus budesonide 200 microg (group 2)
Number of subjects: 213
Study 10669688 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 100 microg plus placebo (group 3)
Number of subjects: 213
Study 9117226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients aged < 60 years
Number of subjects: 72
Study 9117226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients aged >= 60 years
Number of subjects: 72
Study 9117226 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72
Study 9117226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients with metastatic disease
Number of subjects: 72
Study 9117226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients (both age groups)
Number of subjects: 72
Study 8418238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 2 years
Number of subjects: 181
Study 8418238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 3532764 — intervention group
Group type: EXPERIMENTAL
Intervention: metaproterenol sulfate by MDI aerosol (130 micrograms) with tube spacer
Number of subjects: 16
Study 3532764 — intervention group
Group type: EXPERIMENTAL
Intervention: metaproterenol sulfate by MDI aerosol (130 micrograms) without tube spacer
Number of subjects: 16
Study 3532764 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 3532764 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI plus tube spacer
Number of subjects: 16
Study 3532764 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI alone
Number of subjects: 16
Study 29365286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster set with 30s rest (CS30)
Number of subjects: 12
Study 29365286 — intervention group
Group type: COMPARATOR
Intervention: Traditional set (continuous)
Number of subjects: 12
Study 27432930 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks interval after RCT
Number of subjects: 265
Study 27432930 — intervention group
Group type: COMPARATOR
Intervention: 11 weeks interval after RCT
Number of subjects: 265
Study 24955611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 14
Study 24955611 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 14
Study 21890844 — intervention group
Group type: EXPERIMENTAL
Intervention: In control: No alcohol! prevention program
Number of subjects: 213
Study 21890844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 213
Study 20225908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.25 mg/kg
Number of subjects: 0
Study 20225908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg/kg
Number of subjects: 0
Study 20225908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 1 mg/kg
Number of subjects: 0
Study 20225908 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 15 mg/kg
Number of subjects: 0
Study 18545191 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized strength training group (2 sessions per week for 8 weeks)
Number of subjects: 18
Study 18545191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperiodized strength training group (same exercises as periodized but no week-to-week variations)
Number of subjects: 18
Study 18545191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 18
Study 15910150 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-monitors
Number of subjects: 0
Study 15910150 — intervention group
Group type: COMPARATOR
Intervention: Low self-monitors
Number of subjects: 0
Study 15910150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender neutral jobs
Number of subjects: 0
Study 12580689 — intervention group
Group type: COMPARATOR
Intervention: D.A.R.E. Plus
Number of subjects: 6237
Study 12580689 — intervention group
Group type: COMPARATOR
Intervention: D.A.R.E. only
Number of subjects: 6237
Study 12580689 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6237
Study 10100174 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (single dose, 20 g, 34 mg phytoestrogens)
Number of subjects: 51
Study 10100174 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (twice-daily, 20 g, 34 mg phytoestrogens)
Number of subjects: 51
Study 10100174 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate placebo diet
Number of subjects: 51
Study 8705414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast sonography (HyCoSy)
Number of subjects: 66
Study 8705414 — intervention group
Group type: COMPARATOR
Intervention: X-ray hysterosalpingography (HSG)
Number of subjects: 66
Study 1687055 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting GnRHa (D-Trp-6-LHRH) microcapsules administered intramuscularly at menstruation
Number of subjects: 114
Study 1687055 — intervention group
Group type: COMPARATOR
Intervention: FSH and hMG from day 3 of the cycle without GnRHa pre-treatment
Number of subjects: 114
Study 6475827 — intervention group
Group type: COMPARATOR
Intervention: Commercial ergogenic supplement (vitamin, mineral, amino acid, and unsaturated fatty acid complex) administered at a dose of three capsules daily for 4 weeks.
Number of subjects: 20
Study 6475827 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 4 weeks.
Number of subjects: 20
Study 31188839 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 18
Study 31188839 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (SpO2 > 95%)
Number of subjects: 18
Study 31188839 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 31188839 — intervention group
Group type: EXPERIMENTAL
Intervention: Acclimatization over three days
Number of subjects: 18
Study 26050143 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 342
Study 26050143 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 342
Study 25108302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue angiography
Number of subjects: 1823
Study 25108302 — intervention group
Group type: COMPARATOR
Intervention: Scheduled angiography
Number of subjects: 1823
Study 25108302 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1823
Study 25108302 — intervention group
Group type: COMPARATOR
Intervention: Rescue angiography compared to scheduled angiography
Number of subjects: 1823
Study 22594565 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg THC
Number of subjects: 9
Study 22594565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg THC
Number of subjects: 9
Study 22594565 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (5mg and 10mg)
Number of subjects: 9
Study 22594565 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (10mg)
Number of subjects: 9
Study 20862645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments (modulation of the glutamate system, blocking of serotonin 5-HT-3/2a receptors)
Number of subjects: 0
Study 18173155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lin'erlai Prescription (LEL)
Number of subjects: 60
Study 18173155 — intervention group
Group type: COMPARATOR
Intervention: Clomid
Number of subjects: 60
Study 16089148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of xiaoke shen'an capsule and conventional western medicine
Number of subjects: 90
Study 16089148 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 90
Study 11994935 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized verbal administration of GDS-SF
Number of subjects: 0
Study 11994935 — intervention group
Group type: COMPARATOR
Intervention: Non-standardized verbal administration of GDS-SF
Number of subjects: 0
Study 10321295 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7670645 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 883
Study 7670645 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 883
Study 2289388 — intervention group
Group type: EXPERIMENTAL
Intervention: Loestrin
Number of subjects: 391
Study 2289388 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 391
Study 2289388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho 10/11
Number of subjects: 391
Study 2289388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho 7/7/7
Number of subjects: 391
Study 2289388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 391
Study 6246005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 39
Study 6246005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (pivmecillinam and pivampicillin)
Number of subjects: 39
Study 6246005 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin
Number of subjects: 39
Study 30354190 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPA intervention
Number of subjects: 320
Study 28810061 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg IR CTC (equivalent to 88 mg tramadol and 112 mg celecoxib)
Number of subjects: 36
Study 28810061 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg IR tramadol
Number of subjects: 36
Study 28810061 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg celecoxib
Number of subjects: 36
Study 28810061 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg IR tramadol and 100 mg celecoxib
Number of subjects: 36
Study 25970619 — intervention group
Group type: EXPERIMENTAL
Intervention: Alberta Infant Motor Scale (AIMS)
Number of subjects: 0
Study 25970619 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro‐Sensory Motor Developmental Assessment (NSMDA)
Number of subjects: 0
Study 25970619 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AIMS and NSMDA
Number of subjects: 0
Study 25970619 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial assessments using AIMS and NSMDA
Number of subjects: 0
Study 23969953 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental F/Sn/chitosan toothpaste (1,400 ppm F(-), 3,500 ppm Sn(2+), 0.5% chitosan)
Number of subjects: 27
Study 23969953 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental NaF toothpaste (1,400 ppm F(-))
Number of subjects: 27
Study 23969953 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 27
Study 23362725 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic package (YP) including selected pranayama, cleansing practices, and meditation
Number of subjects: 0
Study 23362725 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19819790 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg/daily for 30 days
Number of subjects: 110
Study 19819790 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg/daily for 30 days
Number of subjects: 110
Study 17076614 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD)
Number of subjects: 10
Study 17076614 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 10
Study 15535887 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 282
Study 15535887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 14651355 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma camera uptake method (modified Gates, Gates)
Number of subjects: 133
Study 14651355 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted creatinine clearance method (Cockcroft‐Gault, CG)
Number of subjects: 133
Study 14651355 — intervention group
Group type: COMPARATOR
Intervention: Plasma sample clearance method (PSC)
Number of subjects: 133
Study 9585270 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol IV infusion titrated to electroencephalographic burst suppression during CPB
Number of subjects: 30